- United States
- /
- Medical Equipment
- /
- NasdaqCM:XAIR
Beyond Air First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Beyond Air (NASDAQ:XAIR) First Quarter 2025 Results
Key Financial Results
- Net loss: US$12.2m (loss narrowed by 13% from 1Q 2024).
- US$0.27 loss per share (improved from US$0.45 loss in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Beyond Air EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 13%. Earnings per share (EPS) exceeded analyst estimates by 15%.
Looking ahead, revenue is forecast to grow 84% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 28% from a week ago.
Risk Analysis
You should learn about the 5 warning signs we've spotted with Beyond Air (including 1 which makes us a bit uncomfortable).
Valuation is complex, but we're here to simplify it.
Discover if Beyond Air might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:XAIR
Beyond Air
A commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.
Excellent balance sheet moderate.